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Aims Epidemiological studies suggest that resting heart rate (RHR) is an independent predictor of cardiovascular and all-
cause mortality. Still, this parameter has never been specifically assessed in patients with diabetes mellitus (DM). This
study describes the association between RHR and cardiovascular events (CVE) in patients with coronary artery
disease (CAD) with and without DM.
Methods
and results
The Euro Heart Survey on Diabetes and the Heart enroled 2608 patients with stable CAD, of these 780 (30%) had
known DM. Resting heart rate was registered in 2507 (96%) patients: 1756 (96%) without and 751 (96%) with DM.
Patients were followed with respect to CVE (all-cause mortality, non-fatal myocardial infarction, and stroke) for 1
year. Overall, median RHR was 70 (62–78) b.p.m. The RHR quartile stratification was significantly associated with
outcome in the overall population (P ¼ 0.002 and P ¼ 0.021 for survival and CVE, respectively), whereas it was
not in patients without DM. In patients with DM, the RHR quartiles correlated with survival (P ¼ 0.032). In an
adjusted regression model performed in patients without DM, RHR associated with neither survival [hazard ratio
(HR): 0.97, 95% confidence interval (CI): 0.74–1.27; P ¼ 0.804] nor CVE (HR: 0.85, 95% CI: 0.71–1.01,
P ¼ 0.068). In contrast, a 10-b.p.m. increase in RHR was independently associated with survival (HR: 1.34, 95% CI:
1.06–1.69, P ¼ 0.015), but not with CVE (HR: 0.99, 95% CI: 0.84–1.18; P ¼ 0.359) in patients with DM.
Conclusion The present report, based on patients with stable CAD, is the first to reveal that the association between RHR and
CVE seems to subsist in those with DM, however, not in those without DM.
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Introduction
Over the last 25 years, a significant association between resting
heart rate (RHR) and all-cause and cardiovascular mortality has
been reported in the general population and in patients with
various cardiovascular diseases including hypertension, acute myo-
cardial infarction (AMI), and heart failure or left ventricular dys-
function.1– 5 On the basis of this evidence, RHR has been
included in risk assessment indices for the general population6
and for patients following acute coronary syndromes7 and AMI.8,9
The worldwide prevalence of type 2 diabetes mellitus (DM) will
increase from 4.0% in 1995 to more than 7% by the year 2050.10,11
In addition, this disease is more common within specific groups of
patients, not the least those presenting with coronary artery
disease (CAD). Previous reports from the Euro12 and China
Heart Surveys,13 based on patients with acute and stable CAD,
revealed that approximately one-third of them had known DM.
Surprisingly, the association between RHR, a familiar and accessible
clinical variable, and cardiovascular mortality has never been
specifically assessed in patients with DM.
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The purpose of the present report from the Euro Heart Survey
on Diabetes and the Heart is to test the association between RHR
and cardiovascular events (CVE) in stable CAD patients with and
without DM.
Methods
Between February 2003 and January 2004, the Euro Heart Survey on
Diabetes and the Heart recruited 4961 patients with CAD at 110
centres in 25 European countries. Full details of the survey are
reported previously.14,15 In brief, consecutive patients were screened
for a diagnosis of CAD when admitted to hospital wards or visiting
outpatient clinics at participating centres. All patients were assessed,
investigated, and treated at the discretion of their responsible phys-
icians, according to local institutional practice. Clinical characteristics,
interventions, and results of laboratory tests at the time for recruit-
ment were collected by means of a web-based case record form as
were follow-up data. Of the 4961 originally recruited patients, 94%
(4676) were followed, for at least 1 year (median: 374 days, Q1–
Q3: 366–397), with respect to treatment, survival, and CVE (all-cause
mortality, myocardial infarction, and stroke). To limit the autonomic
influences on the cardiovascular system due to acute stress caused
by the actual disease condition,16 the present report only included
patients with stable CAD (Figure 1). As in previous reports from the
Euro Heart Survey,17 to avoid considering patients that withdraw treat-
ment within the year of follow-up, the medication use included in the
present analysis was that prescribed at discharge and recorded at
follow-up.
Definitions
Character of admission: on the basis of the clinical presentation at
enrolment, the patients were categorized as having acute or stable
CAD. Acute CAD was defined as not-prescheduled hospital admis-
sions due to acute coronary syndromes, aggravated symptoms of
heart failure, or arrhythmias. Stable CAD was defined as elective con-
sultations in an outpatient clinic and scheduled hospital admissions for
diagnostic procedures, treatment adjustments, or elective interven-
tions related to CAD.
Glucometabolic state: the presence of known DM was recognized if
this diagnosis was established prior to enrolment according to the
WHO classification,18 reported in the medical records, declared
directly by the patient, or revealed by the use of glucose-lowering
drugs.
RHR: RHR was recorded at enrolment following 5 min of sitting rest
to be reported as the average of two measurements.
Statistical analysis
Continuous variables are expressed as medians with lower and upper
quartiles (Q1–Q3), and categorical variables as counts and percen-
tages. Continuous variables were compared between strata by
means of analysis of variance, and categorical variables in contingency
tables by means of Pearson’s x2 test. The Kaplan–Meier curves were
computed for all-cause mortality and the composite endpoint of CVE
(including all-cause mortality, myocardial infarction, and stroke). The
log-rank test was used to test for differences in the unadjusted survival
curves. The Cox proportional-hazard regression was used to test cor-
relation of 1-year events with RHR, DM state, and the interaction term
of these two parameters. If the interaction term between RHR and
DM was significant, the subsequent multiple Cox proportional-hazard
regression models were to be performed on patients with and without
DM separately. Forward- and backward-stepwise selection were per-
formed to adjust the models for confounders detected from the base-
line characteristics and medications at follow-up (Table 1). Assumption
of proportional hazards was assessed and satisfied by visual inspection
of the log-minus-log survival curves for the RHR quartiles distribution.
A two-sided P-value of ,0.05 was considered statistically significant; all
analyses were performed with SPSS 16.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Ethical consideration
The protocol was approved by the Ethics Committee at Karolinska
Institutet, Stockholm, Sweden, and National Survey coordinators
took the responsibility for assuring compliance with the ethical
requirements in each country. The patients were enroled following
an oral and/or written informed consent with respect to the local
rules and were informed about the follow-up after 1 year.
Results
Of the 2608 patients with stable CAD, enroled during an outpati-
ent clinic or a scheduled hospital admission, 780 (30%) had known
DM (Figure 1). Resting heart rate at enrolment was available in a
total of 2507 (96%) patients: 1756 (96%) without and 751 (96%)
with DM. Overall, median RHR was 70 (62–78; minimum 40,
maximum 140) b.p.m.; 70 (60–76; minimum 40, maximum 140)
and 75 (62–78; minimum 40, maximum 126) b.p.m., respectively,
in patients without and with DM. Comparison of baseline charac-
teristics and medications at follow-up within RHR quartiles in
patients with and without DM is detailed in Table 1. One-year
events are reported in Table 2 by RHR quartiles and by diabetic
state. The Kaplan–Meier curves for all-cause mortality and survival
free from myocardial infarction and stroke emphasize 1-year prog-
nosis by RHR quartiles in the overall population and in patients
with and without DM, respectively (Figure 2). The RHR quartile
stratification was associated with 1-year outcome in the overall
population (log-rank test: P ¼ 0.002 and P ¼ 0.021 for survival
and CVE, respectively), whereas it did not correlate to all-cause
mortality or CVE in patients without DM. In contrast, the RHR
quartile stratification was associated with 1-year all-cause mortality
(log-rank test P ¼ 0.032) in patients with DM.
Figure 1 Description of the study population. DM, diabetes
mellitus.
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Detailed results of the Cox regression models performed are
reported in Table 3. In the unadjusted Cox regression model run
on the total population, a 10-b.p.m. increase in RHR correlated
with worse 1-year survival [hazard ratio (HR): 1.25, 95% confi-
dence interval (95% CI): 1.11–1.40, P, 0.001] and combined
CVE (HR: 1.10, 95% CI: 1.01–1.21, P ¼ 0.036). The interaction
term within RHR and diabetic state was associated with both
1-year survival (HR: 1.10, 95% CI: 1.04–1.16, P, 0.001) and
combined CVE (HR: 1.09, 95% CI: 1.06–1.13, P, 0.001). Adjust-
ing for available confounders, RHR association with 1-year events
did not retain statistical significance in patients without DM con-
cerning both survival (HR: 0.97, 95% CI: 0.74–1.27, P ¼ 0.804)
and CVE (HR: 0.85, 95% CI: 0.71–1.01, P ¼ 0.068). In contrast, a
10-b.p.m. increase in RHR was independently associated with
1-year survival (HR: 1.34, 95% CI: 1.06–1.69, P ¼ 0.015) in patients
with DM but not with 1-year combined CVE (HR: 0.99, 95% CI:
0.84–1.18, P ¼ 0.359).
Discussion
The present report tests the association between RHR and CVE in
stable CAD patients with and without DM. The main finding is that
although high RHR was associated with worse 1-year survival in
the total CAD population, the association, following adjustments
for available confounders, only remained in patients with DM.
A significant correlation between RHR, a familiar and accessible
clinical variable, and all-cause and cardiovascular mortality has
been reported in the general population and in patients with
various cardiovascular diseases.1 –5 Diabetes mellitus being an
increasingly prevalent disorder especially in patients with cardio-
vascular disease, and the fact that none of the previous obser-
vations were performed separating DM from non-DM patients
may have been misleading. To the best of our knowledge, this is
the first study testing the association between RHR and cardiovas-
cular outcome comparing CAD patients with and without DM.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Baseline characteristics and medications at follow-up (data presented as percentages if not otherwise stated) of
patients with stable coronary artery disease by resting heart rate quartiles (Q1 ≤ 62, 62 < Q2 ≤ 70, 70 < Q3 ≤ 78, and
Q4 > 78 b.p.m.) and diabetic state (P-value by analysis of variance and Pearson’s x2 test for comparison of continuous and
categorical variables between resting heart rate quartiles within diabetic state)
Variable Total Non-DM (n 5 1756) P-value DM (n5 751) P-value
All Q1 Q2 Q3 Q4 All Q1 Q2 Q3 Q4
Males 72 74 77 74 69 72 0.012 69 76 74 66 66 0.083
Median age (years) 66 66 64 65 67 67 0.001 68 68 66 70 68 0.127
Current smokers 16 17 14 17 17 20 0.065 12 15 9 12 12 0.314
Hypertension 67 62 60 60 69 63 0.063 77 72 82 74 82 0.086
Hyperlipidaemia 73 73 77 72 74 69 0.228 72 80 72 69 70 0.063
CVD 14 12 9 6 17 18 0.001 17 9 13 20 25 0.001
PAD 18 14 8 10 22 17 0.001 27 17 19 39 31 0.001
Previous
CAD 25 25 21 21 29 31 0.001 26 23 19 38 26 0.001
CHF 25 21 11 16 30 33 0.001 33 21 20 45 41 0.001
PCI 56 55 51 56 57 56 0.229 57 58 49 65 56 0.019
CABG 32 35 42 39 27 30 0.001 26 27 28 23 25 0.675
Medications at follow-up
BB 76 76 78 75 80 71 0.023 74 74 77 74 73 0.782
ACE-I/ARBs 68 64 60 63 69 67 0.022 79 75 68 84 84 0.062
Oral anti-PLTs 78 79 95 88 79 69 0.001 77 96 81 79 77 0.001
Statins 68 76 80 79 75 69 0.002 73 73 73 71 74 0.947
DM, diabetes mellitus; CVD, cerebrovascular disease; PAD, peripheral artery disease; CAD, coronary artery disease; CHF, congestive heart failure; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; BB, b-blockers; ACE-I/ARBs, renin-angiotensin system blockers; PLTs, platelets.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 One-year events (shown as counts and %)
stratified by resting heart rate quartiles (Q1–Q4) in the





All NDM DM All NDM DM
Q1 661 (510/151)a 14 (2) 11 (2) 3 (2) 42 (6) 29 (6) 13 (9)
Q2 600 (443/157)a 16 (3) 11 (2) 5 (3) 35 (6) 23 (5) 12 (8)
Q3 645 (438/207)a 21 (3) 11 (2) 10 (5) 60 (9) 33 (7) 27 (13)
Q4 601 (365/236)a 21 (3) 12 (3) 19 (8) 53 (9) 19 (5) 34 (14)
Total 82 (3) 45 (3) 37 (5) 190 (8) 104 (6) 86 (11)
NDM, patients without diabetes mellitus; DM, patients with diabetes mellitus;
CVE, cardiovascular events.
aPatients without and with diabetes mellitus, respectively.
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Figure 2 The Kaplan–Meier curves for survival (A, C, and E) and survival free from myocardial infarction and stroke (B, D, and F) by resting
heart rate quartiles in the overall population (A and B) and in patients without (C and D) and with (E and F ) diabetes mellitus (blue, Q1 ≤ 62;
green, 62 , Q2 ≤ 70; yellow, 70, Q3 ≤ 78; purple, Q4 . 78 b.p.m.; P-value by log-rank test).
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Oxygen consumption is heart-rate proportional,19 and in pre-
vious experimental studies, high heart rate has been related to
arterial rigidity,20 extent and progression of coronary artery ather-
osclerosis,21,22 and likelihood of disrupting atherosclerotic
plaques.23 In the case of concomitant DM, there are several
additional reasons that may increase the negative prognostic influ-
ence of a high RHR. Hyperglycaemia enhances the tendency for
plaque destabilization by decreasing endothelium-derived nitric
oxide availability24 and synthesis of collagen and by increasing reac-
tive oxygen species25 and matrix metalloproteinases production.26
In addition, the dominant metabolic pathway for myocardial energy
production in DM patients relies on non-esterified fatty acids,
which compared with glucose oxidation, requires higher basal
oxygen levels.27 So far, only few studies addressed the prognostic
role of RHR in diabetic-specific populations, and no studies
focused on DM patients with cardiovascular disease. A previous
experience on 523 DM patients (221 with type 1 and 302 type 2
DM) related RHR to 20-year increased mortality only within sub-
jects with type 2 DM.28 Further support derives from 475 type 2
diabetic patients included in the Bremen Diabetes Study.29 In this
observational study, an elevated heart rate (.75 b.p.m.) related
to a 5-year increase in cardiovascular death (HR: 3.3, 95% CI:
1.33–8.19). The aforementioned reasons all support the finding
of the present report that high RHR, in DM patients, may relate
to a more dismal survival.
Cardiac autonomic neuropathy is a common chronic compli-
cation in patients with DM. Despite this, high RHR by itself is
not considered to provide a reliable diagnostic criterion of
cardiac autonomic neuropathy. However, in the absence of
other signs, it may surely reflect a relative increase in the sympath-
etic tone associated with vagal impairment.30 This condition, based
on a meta-analysis of 15 studies including 2900 subjects with DM,
has been related to a three times greater relative risk of mor-
tality.31 The difference between DM and non-DM patients with
CAD in the association of RHR with CVE may, therefore, be
that increasing RHR reflects a parasympathetic disturbance and
adrenergic dominance more easily determinable, and transferable
in 1-year outcome, within patients with DM. In this perspective,
it is of interest that available information reports on the association
between intensive DM management and lower RHR in type 1
diabetes.32
The finding that high RHR was not independently associated
with 1-year survival in patients without DM most probably relies
on the two following points. First, high RHR presents a plausible
minor harmful effect in a non-DM than in a DM setting. Second,
a follow-up duration of 1 year may be a too short-term period
to detect significant differences in events of a relatively ’low’-risk
population as that of without DM.
Study limitations
The present report is based on a secondary utilization of an exist-
ing material that offered an opportunity, not often available in
similar settings, to make the analyses on which the article is
focused. The population included and the 1-year follow-up may
be experienced as limited for an epidemiologic study. Still, the find-
ings generate a hypothesis which may be further elucidated in
greater populations. Relevant differences in baseline characteristics
are present between patients with and without diabetes. Despite
adjusting the multiple Cox proportional-hazard regression
models for available confounders differences in baseline character-
istics cannot be excluded as, at least, partial reasons for the
findings.
In conclusion, the present report based on a large European
survey on patients with CAD is the first to reveal that the associ-
ation between RHR and CVE seems to be limited to those with
DM. In light of the present data, previous observations on the
importance of RHR for cardiovascular prognosis may have been
misleading since they were not controlled for the DM state. The
present finding warrants consideration when planning future
investigations.
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Table 3 Upper part: Cox proportional-hazard regression testing the relation between resting heart rate in 10 b.p.m.,
the presence of diabetes mellitus, and the interaction between these two parameters with 1-year all-cause mortality and
cardiovascular events; lower part: crude and adjusted analysis of the relation between RHR in 10 b.p.m. and all-cause
mortality and combined cardiovascular events in patients with stable coronary artery disease without and with diabetes
mellitus
Population Parameter HR All-cause
mortality 95% CI
P-value HR CVE 95% CI P-value
Total RHR/10 b.p.m. 1.25 1.11–1.40 ,0.001 1.10 1.01–1.21 0.036
DM 1.85 1.22–2.82 0.004 1.91 1.44–2.53 ,0.001
Interaction terma 1.10 1.04–1.16 ,0.001 1.09 1.06–1.13 ,0.001
Non-DM RHR/10 b.p.m. 1.15 0.97–1.37 0.110 1.04 0.91–1.19 0.555
Adjustedb RHR/10 b.p.m. 0.97 0.74–1.27 0.804 0.85 0.71–1.01 0.068
DM RHR/10 b.p.m. 1.41 1.14–1.74 ,0.001 1.14 0.98–1.33 0.086
Adjustedc RHR/10 b.p.m. 1.34 1.06–1.69 0.015 0.99 0.84–1.18 0.359
HR, hazard ratio; 95% CI, 95% confidence interval. Other abbreviations as in previous tables.
aResting heart rate (10 b.p.m.) multiplied by diabetic status.
bAdjusted for gender; age; cerebrovascular disease; peripheral artery disease; previous coronary artery disease, congestive heart failure, CABG; b-blockers, ACE-inihibitors/ARBs,
oral antiplatelets, and statins at follow-up.
cAdjusted for cerebrovascular disease; peripheral artery disease; previous coronary artery disease, congestive heart failure, PCI; oral antiplatelets at follow-up.
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